Molecular Subtyping of Cardiac Remodeling: Contemporary Insights, Clinical Implications, and Future Directions

Abstract

Cardiac remodeling, a dynamic process involving structural and functional changes of the myocardium in response to injury or stress, underlies the progression of various cardiovascular diseases. Recent advances in molecular profiling techniques have enabled the identification of distinct molecular subtypes of cardiac remodeling, offering new perspectives for personalized diagnosis, risk stratification, and targeted therapy. This review synthesizes the current evidence on molecular subtyping of cardiac remodeling, highlighting the epidemiology, underlying mechanisms, clinical features, diagnostic approaches, therapeutic strategies, and guideline recommendations, with an emphasis on translating molecular insights into clinical practice.

Introduction

Cardiac remodeling is a hallmark of many cardiovascular pathologies, including heart failure, ischemic heart disease, and cardiomyopathies. Traditionally assessed through imaging and histopathology, remodeling is now recognized as a heterogeneous process with distinct molecular signatures. The emergence of high-throughput genomics, transcriptomics, proteomics, and metabolomics has facilitated the classification of cardiac remodeling into molecular subtypes, each characterized by unique biological pathways and clinical trajectories. Understanding these subtypes is crucial for optimizing patient management and developing precision medicine strategies in cardiology.

Epidemiology / Disease Burden

Cardiac remodeling contributes significantly to the global burden of heart failure, which affects over 64 million individuals worldwide. Remodeling is commonly observed after myocardial infarction, in hypertensive heart disease, and in various cardiomyopathies, substantially increasing morbidity and mortality. Epidemiological studies indicate that molecular subtypes of remodeling may have distinct prevalence patterns, influenced by genetic, environmental, and demographic factors. For instance, inflammatory-driven and fibrosis-dominant subtypes may predominate in different patient populations, impacting treatment responses and prognoses.

Pathophysiology

The pathophysiological basis of cardiac remodeling involves complex interplay between cellular, molecular, and extracellular matrix components. Molecular subtyping has revealed that remodeling can be broadly categorized based on dominant pathways, such as inflammation, neurohormonal activation, oxidative stress, metabolic dysregulation, and fibrosis. Transcriptomic and proteomic analyses have identified key molecular drivers, including cytokines, growth factors, matrix metalloproteinases, and non-coding RNAs, that orchestrate these remodeling processes. Notably, subtypes characterized by heightened inflammatory signaling exhibit rapid progression and poor outcomes, while those with predominant metabolic alterations may respond differently to therapy.

Risk Factors

Risk factors for cardiac remodeling include traditional cardiovascular risk factors hypertension, diabetes mellitus, obesity, dyslipidemia, and ischemic insults as well as genetic predispositions and environmental exposures. Molecular profiling has uncovered subtype-specific risk factors; for example, certain single nucleotide polymorphisms (SNPs) in genes regulating extracellular matrix turnover are associated with fibrotic remodeling, while variants affecting immune regulation predispose to inflammatory subtypes. Additionally, comorbidities such as chronic kidney disease and autoimmune conditions may modulate the molecular phenotype of remodeling.

Clinical Features

Clinically, the manifestations of cardiac remodeling depend on the underlying molecular subtype. Common features include symptoms of heart failure (dyspnea, fatigue, edema), arrhythmias, and progressive decline in cardiac function. Fibrosis-dominant subtypes often present with restrictive physiology and diastolic dysfunction, whereas inflammatory subtypes may show rapid systolic decline and increased biomarker levels (e.g., troponins, natriuretic peptides, inflammatory cytokines). Recognizing these patterns facilitates early identification and tailored management of at-risk patients.

Diagnosis

Diagnosis of molecular subtypes of cardiac remodeling requires integration of clinical assessment, advanced imaging (echocardiography, cardiac MRI), and molecular profiling. Biomarker panels (e.g., galectin-3, ST2, miRNAs) serve as surrogates of specific remodeling pathways. Recent studies demonstrate that transcriptomic and proteomic signatures, obtained from endomyocardial biopsy or circulating blood, can reliably classify remodeling subtypes. Machine learning algorithms are increasingly used to analyze multi-omics data and enhance diagnostic accuracy, facilitating early intervention and risk stratification.

Treatment & Management

Therapeutic approaches to cardiac remodeling traditionally include neurohormonal blockade (ACE inhibitors, beta-blockers, mineralocorticoid receptor antagonists), device therapy, and lifestyle modification. Molecular subtyping enables more precise targeting of therapy; for example, antifibrotic agents (pirfenidone, mineralocorticoid antagonists) are prioritized in fibrosis-dominant subtypes, while immunomodulatory therapies (colchicine, IL-1 inhibitors) may benefit inflammatory phenotypes. Personalized management strategies are emerging, with ongoing research into targeted small molecules, gene therapy, and RNA-based interventions tailored to molecular profiles.

Recent Advances / Emerging Therapies

Recent years have witnessed remarkable progress in the molecular characterization of cardiac remodeling. Single-cell RNA sequencing, spatial transcriptomics, and mass spectrometry-based proteomics have unraveled cellular and molecular heterogeneity within remodeled myocardium. Novel therapeutics, such as RNA interference drugs, antisense oligonucleotides, and monoclonal antibodies targeting specific molecular pathways, are in clinical development. Additionally, multi-omics-based risk scores and digital pathology tools are enhancing patient stratification, guiding clinical trials, and informing drug development in this evolving field.

Guideline Recommendations

Major cardiovascular societies increasingly recognize the clinical value of molecular subtyping in cardiac remodeling. The 2022 ESC and ACC/AHA heart failure guidelines advocate for biomarker-guided management and recommend molecular profiling in select cases to inform prognosis and guide advanced therapies. Integration of molecular subtyping into routine practice remains limited by cost, accessibility, and need for standardized protocols, but ongoing research and guideline updates are expected to expand its clinical utility.

Conclusion

Molecular subtyping has transformed our understanding of cardiac remodeling, elucidating distinct biological pathways and clinical phenotypes that underpin disease progression and therapeutic response. As multi-omics technologies become more accessible and integrated into clinical workflows, molecular subtyping promises to enhance precision medicine in cardiology, enabling individualized risk stratification and targeted therapy. Continued research, interdisciplinary collaboration, and harmonization of guidelines will be essential to realize the full potential of molecular subtyping in improving patient outcomes in cardiac remodeling.